In vitro activity of ertapenem:: review of recent studies

被引:66
作者
Wexler, HM
机构
[1] GLA VA Healthcare Syst, Wadsworth Anaerobe Lab, Los Angeles, CA 90073 USA
[2] Univ Calif Los Angeles, Sch Med, Los Angeles, CA USA
关键词
susceptibility; resistance; carbapenems; antimicrobial agents;
D O I
10.1093/jac/dkh204
中图分类号
R51 [传染病];
学科分类号
100401 ;
摘要
Ertapenem is a long-acting, 1beta-methyl parenteral Group 1 carbapenem antibiotic that has a broad antibacterial spectrum and once-a-day dosing supported by clinical studies. Ertapenem is active against both Gram-positive and Gram-negative bacteria, including Enterobacteriaceae, Streptococcus pneumoniae and most species of anaerobic bacteria. Isolates from a variety of infections (intra-abdominal infections, skin/ soft-tissue infections, community-acquired pneumonia, pelvic infections and urinary tract infections) are inhibited by ertapenem. It has restricted activity against nosocomial pathogens such as Pseudomonas aeruginosa, Acinetobacter species, methicillin-resistant staphylococci and enterococci. Ertapenem has potent activity against the majority of anaerobic isolates from intra-abdominal infections, and against most of the aerobes isolated from these infections, with the exceptions of the nosocomial pathogens mentioned above. MIC(90)s for most species of Enterobacteriaceae were <1 mg/L, significantly lower than those of imipenem. MIC(90)s for most Bacteroides fragilis group isolates ranged from 1 to 4 mg/L, and MIC(90)s were species specific for Clostridium, ranging from 0.06 mg/L for Clostridium perfringens to 4 mg/L for Clostridium clostridioforme. Ertapenem was equivalent to or better than piperacillin-tazobactam in activity against most anaerobic species isolated from these infections, and was more potent than piperacillin-tazobactam and ceftriaxone against the most common skin pathogens (e.g. methicillin-susceptible Staphylococcus aureus). Ertapenem was highly active against most of the pathogens isolated from patients with community-acquired pneumonia, except for isolates of methicillin-resistant S. aureus (which are infrequent causes of community-acquired infection); these isolates were also resistant to ceftriaxone. Resistance to ertapenem is most commonly attributable to a variety of mechanisms including alterations in penicillin-binding proteins in Gram-positive organisms, and combinations of potent metallo-beta-lactamase enzymes, porin protein defects and efflux pumps in Gram-negative organisms.
引用
收藏
页码:11 / 21
页数:11
相关论文
共 53 条
[1]   Ertapenem (MK-0826), a new carbapenem: comparative in vitro activity against clinically significant anaerobes [J].
Aldridge, KE .
DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2002, 44 (02) :181-186
[3]   THE BACTERIOLOGY OF GANGRENOUS AND PERFORATED APPENDICITIS - REVISITED [J].
BENNION, RS ;
BARON, EJ ;
THOMPSON, JE ;
DOWNES, J ;
SUMMANEN, P ;
TALAN, DA ;
FINEGOLD, SM .
ANNALS OF SURGERY, 1990, 211 (02) :165-171
[4]   In vitro activities of MK-0826 and 16 other antimicrobials against Bacteroides fragilis group strains [J].
Betriu, C ;
Sánchez, A ;
Palau, ML ;
Gómez, M ;
Picazo, JJ .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2001, 45 (08) :2372-2374
[5]  
Bonfiglio G, 2002, EXPERT OPIN INV DRUG, V11, P529
[6]   A FUNCTIONAL CLASSIFICATION SCHEME FOR BETA-LACTAMASES AND ITS CORRELATION WITH MOLECULAR-STRUCTURE [J].
BUSH, K ;
JACOBY, GA ;
MEDEIROS, AA .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1995, 39 (06) :1211-1233
[7]  
Bush K, 2001, CLIN INFECT DIS, V32, P1085, DOI 10.1086/319610
[8]   A review of its microbiologic, pharmacokinetic and clinical aspects [J].
Cunha, BA .
DRUGS OF TODAY, 2002, 38 (03) :195-213
[9]  
Foxman B, 2002, AM J MED, V113, p5S
[10]   In vitro activity of ertapenem against common clinical isolates in relation to human pharmacokinetics [J].
Friedland, I ;
Mixson, LA ;
Majumdar, A ;
Motyl, M ;
Woods, GL .
JOURNAL OF CHEMOTHERAPY, 2002, 14 (05) :483-491